QIAGEN Adds Promising New Biomarker to Pipeline of Personalized Healthcare Assays to Improve Diagnosis of Blood Disorders - Seite 3

of the U.S. Securities Exchange Act of 1934, as amended. To the
extent that any of the statements contained herein relating to
QIAGEN's products, markets, strategy or operating results, including
without limitation its expected operating results, are
forward-looking, such statements are based on current expectations
and assumptions that involve a number of uncertainties and risks.
Such uncertainties and risks include, but are not limited to, risks
associated with management of growth and international operations
(including the effects of currency fluctuations, regulatory processes
and dependence on logistics), variability of operating results and
allocations between customer classes, the commercial development of
markets for our products in applied testing [http://www.qiagen.com/A
bout-Us/Press-Releases/PressReleaseView/?PressReleaseID=405&lang=EN ]
, personalized healthcare, clinical research, proteomics [http://www
.qiagen.com/About-Us/Press-Releases/PressReleaseView/?PressReleaseID=
405&lang=EN ] , women's health/HPV [http://www.qiagen.com/About-Us/P
ress-Releases/PressReleaseView/?PressReleaseID=405&lang=EN ] testing
and nucleic acid [http://www.qiagen.com/About-Us/Press-Releases/Pres
sReleaseView/?PressReleaseID=405&lang=EN ] -based molecular
diagnostics [http://www.qiagen.com/About-Us/Press-Releases/PressRele
aseView/?PressReleaseID=405&lang=EN ] ; changing relationships with
customers, suppliers and strategic partners; competition; rapid or
unexpected changes in technologies; fluctuations in demand for
QIAGEN's products (including fluctuations due to general economic
conditions, the level and timing of customers' funding, budgets and
other factors); our ability to obtain regulatory approval of our
products; difficulties in successfully adapting QIAGEN's products to
integrated solutions and producing such products; the ability of
QIAGEN to identify and develop new products and to differentiate and
protect our products from competitors' products; market acceptance of
QIAGEN's new products, the consummation of acquisitions, and the
integration of acquired technologies and businesses. For further
information, please refer to the discussions in reports that QIAGEN
has filed with, or furnished to, the U.S. Securities and Exchange
Commission (SEC).



Contacts:

Public Relations:
Dr. Thomas Theuringer
Director Public Relations
[phone]
[phone]

Email: [e-mail]

http://www.twitter.com/qiagen
pr.qiagen.com [http://www.qiagen.com/About-Us/Press-and-Media ]

Investor Relations:
John Gilardi
Vice President Corporate Communications and Investor Relations
[phone]
[phone]

Email: [e-mail]
ir.qiagen.com [http://www.qiagen.com/About-Us/Investors ]



ots Originaltext: Qiagen N.V.
Im Internet recherchierbar: http://www.presseportal.de